Advanced search
Publication Cover
Postgraduate Medicine Volume 130, 2018 - Issue 3
Submit an article Journal homepage
235
Views
14
CrossRef citations to date
0
Altmetric
Clinical Features - Original Research

Risk of osteoporosis in microscopic colitis

Signe WildtMedical Department, Zealand University Hospital Koege, Koege, Denmark;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6391-1782View further author information
ORCID Icon,
Lars K. MunckMedical Department, Zealand University Hospital Koege, Koege, Denmark;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkORCID Iconhttp://orcid.org/0000-0002-5014-8260View further author information
ORCID Icon,
Sabine BeckerDiagnostic Centre, Regional Hospital Silkeborg, Silkeborg, Denmark;University Research Clinic for Innovative Patient Pathways, Aarhus University, Aarhus, DenmarkView further author information
,
Helle BrockstedtDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, DenmarkView further author information
,
Ole K. BonderupDiagnostic Centre, Regional Hospital Silkeborg, Silkeborg, Denmark;University Research Clinic for Innovative Patient Pathways, Aarhus University, Aarhus, DenmarkORCID Iconhttp://orcid.org/0000-0003-3199-3474View further author information
ORCID Icon &
Mette F. HitzMedical Department, Zealand University Hospital Koege, Koege, Denmark;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkView further author information
Pages 348-354 | Received 19 Dec 2017, Accepted 13 Feb 2018, Published online: 22 Feb 2018

References

  • Pardi D, Kelly CP. Microscopic colitis. Gastroenterology. 2011;140:1155–1165.
  • Bjørnbak C, Engel PJH, Nielsen PL, et al. Microscopic colitis: clinical findings, topography, and persistence of histopathological subgroups. Aliment Pharmacol Ther. 2011;34:1225–1234.
  • Chande N, McDonald JW, Macdonald JK. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev. 2008 Apr;16(2):CD006096.
  • Chande N, McDonald JW, Macdonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2008 Apr;16(2):CD003575.
  • (No authors listed). Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991 Jan;90(1):107–110.
  • Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003 Aug;15(8):857–864.
  • Campieri M, Ferguson A, Doe W, et al.; The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut. 1997;41:209–214.
  • Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol. 2004;16:47–54.
  • Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int. 2008 Apr;82(4):249–257.
  • Schoon EJ, Bollani S, Mills PR, et al; Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005 Feb;3(2):113–121.
  • Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2015;10(3):239–254.
  • Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009 Jul;122(7):599–604.
  • Vigren L, Sjöberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? Scand J Gastroenterol. 2011 Nov;46(11):1334–1339.
  • Lorinczy K, Lakatos G, Müllner K, et al. Low bone mass in microscopic colitis. BMC Gastroenterol. 2011 May;19(11):58.
  • Langner C, Aust D, Ensari A, et al; Working Group of Digestive Diseases of the European Society of Pathology (ESP) and the European Microscopic Colitis Group (EMCG). Histology of Microscopic Colitis-Review with a Practical Approach for Pathologists. Histopathology. 2015 Apr;66(5):613–626.
  • Hjortwang H, Tyske C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis. 2009;15:1875–1881.
  • Hjortswang H, Tysk C, Bohr J, et al. Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis. 2011 Feb;43(2):102–109.
  • Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139(3):194–204.
  • Torres-del-Pliego E, Vilaplana L, Güerri-Fernández R, et al. Measuring bone quality. Curr Rheumatol Rep. 2013;15:373.
  • Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391–420.
  • van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative dosis. Rheumatology (Oxford). 2000 Dec;39(12):1383–1389.
  • Münch A, Tysk C, Bohr J, et al. Smoking status influences clinical outcome in collagenous colitis. J Crohns Colitis. 2016;449–454.
  • Lichtenstein GR, Travis S, Danese S, et al. Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis. J Crohns Colitis. 2015 Sep;9(9):738–746.
  • Lichtenstein GR, Danese S, Ballard ED, et al. Effect of Budesonide MMX 6 mg on the Hypothalamic-Pituitary-Adrenal (HPA) axis in patients with ulcerative colitis: results from a phase iii, 12 month safety and extended use study. Gastroenterology. 2012;142 Suppl 1:785.
  • Lichtenstein GR, Bengtsson B, Hapten-White L, et al. Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009 Mar 15;29(6):643–653.
  • Harbord M, Annese V, Vavricka SR, et al; European Crohn’s and Colitis Organisation. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016 Mar;10(3):239–254.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.